Lactobacillus rhamnosus Probio-M9 combined with PD-1 inhibitor to improve tumor treatment effect

Cancer treatment is a major problem in today's medical field. Its traditional treatment methods include surgery, chemotherapy and radiotherapy, but they are generally characterized by low cure rate, easy recurrence, and large side effects . However, in recent years, immune checkpoint inhibitors (ICBs) represented by PD-1/PD-L1 inhibitors have gradually become a new way of cancer treatment! The main principle is to block the binding of the receptors and ligands of immune checkpoint molecules such as PD-1/PD-L1 and CTLA-4, thereby effectively preventing the inhibition of T cells by co-suppressors and promoting the function of T cells. Achieve the removal of tumor cells! Immune checkpoint inhibitors represented by PD-1/PD-L1 inhibitors alone still have many problems in cancer treatment, the most important being the low response rate! Studies have shown that the response rate of cancer patients treated with drugs targeting PD-1/PD-L1 alone does not exceed 40% . In addition, there is a slow onset, the onset time is more than 12 weeks; the treatment effect is poor; it is easy to cause minor side effects and so on . As an important microecological preparation, probiotics have been found in previous experiments that Lactobacillus rhamnosus can participate in the regulation of the immune system and exert probiotic effects. Modulators of immune signaling pathways are involved in scientific research on tumor therapy . 　　 　　Probio-M9 combined with PD-1 in the treatment of gastrointestinal tumors 　　Mice aged 6-8 weeks were selected to participate in the study and divided into 4 groups (10 mice in each group), namely control group (normal saline + isotype antibody), Probio-M9 single treatment group (Probio-M9 + isotype antibody), PD- 1 Antibody monotherapy group (normal saline + PD-1 antibody) and combined treatment group (Probio-M9 + PD-1 antibody) . After the end of adaptive feeding, the mice were treated with antibiotics and inoculated with CT26 cells to simulate tumors. The experiments were carried out for 24 days, and the tumor size was measured after the experiment . 　　 　　 　　The results showed that the combined treatment of Lactobacillus rhamnosus Probio-M9 and PD-1 antibody can significantly inhibit the growth of tumors in the digestive tract, and can significantly improve the survival of mice, and the therapeutic effect is better than that of PD-1 antibody alone . This indicates that Lactobacillus rhamnosus Probio-M9 can stimulate the immune system and promote the enrichment of various immune cells to enhance PD-1 response, inhibit tumor growth, improve survival rate, and prolong survival .   　　Probio-M9 and mixed probiotics containing Probio-M9 in PD-1 antibody therapy were compared and 　　compared Lactobacillus rhamnosus Probio-M9 single strain and Lactobacillus rhamnosus Probio-M9 complex strain on tumor treatment effect. Among them, Lactobacillus casei Zhang was also added to the compound strain formula; the relative tumor proliferation rate, relative tumor inhibition rate and other indicators of mice were detected . 　　The results showed that the combined application of Lactobacillus rhamnosus Probio-M9 and aPD-1 can enhance the effect of aPD-1 on tumor inhibition, and its relative tumor inhibition rate can reach up to 32%, while the tumor proliferation rate is only 68%; the therapeutic effect is excellent. for the treatment of compound strains . This indicates that a sufficient amount of Lactobacillus rhamnosus Probio-M9 can promote the response of mice to PD-1 treatment, and the single strain can exert a corresponding probiotic effect compared with the composite strain . 　　In conclusion, the combined treatment of Lactobacillus rhamnosus Probio-M9 and PD-1 antibody can significantly inhibit tumor growth, and the effect is better than that of PD-1 treatment alone; Probio-M9 can also stimulate the immune system and promote the enrichment of various immune cells. To increase the response rate of PD-1, inhibit tumor growth, and improve survival rate to achieve prolonged survival . The experiment also found that a sufficient amount of Probio-M9 single-strain combination therapy can achieve a good probiotic effect, and its relative tumor inhibition rate is as high as 32%! 　　Ketuo Bio has always adhered to scientific research and continuous innovation, and cooperated with many domestic universities, research institutes and enterprises to isolate, identify and preserve 21,268 strains of lactic acid bacteria from naturally fermented foods, healthy people's intestines and breast milk from all over Asia, and built an Asian The largest resource bank of lactic acid bacteria strains . A total of 60 clinical trials have been carried out in cooperation with more than ten domestic top-three hospitals, and the effect is remarkable . In the future, Ketuo Bio will continue to innovate, continue to create "Chinese bacteria" and adhere to the industrial application of its own strains to help the healthy development of China's probiotics industry!   Disclaimer: This article only represents the author's personal opinion and has nothing to do with China Probiotics Network . Its originality and the text and content stated in the text have not been verified by this site, and this site does not make any guarantee or commitment to the authenticity, completeness and timeliness of this text and all or part of its content and text. Readers are only for reference and please Verify the relevant content yourself .   Copyright Notice 1. Some articles reproduced on this site are not original, and their copyright and responsibility belong to the original author . 2. All reprinted articles, links and pictures on this website are for the purpose of conveying more information, and the source and author are clearly indicated. Media or individuals who do not wish to be reprinted can contact us for infringing information that can provide sufficient evidence. , bio149 will be deleted within 12 hours after confirmation . 3. Users are welcome to submit original articles to 86371366@qq. com, which will be published on the homepage after review, and the copyright and responsibility of the articles belong to the sender .

　　Immune checkpoint inhibitors represented by PD-1/PD-L1 inhibitors alone still have many problems in cancer treatment, the most important being the low response rate! Studies have shown that the response rate of cancer patients treated with drugs targeting PD-1/PD-L1 alone does not exceed 40%
.
In addition, there is a slow onset, the onset time is more than 12 weeks; the treatment effect is poor; it is easy to cause minor side effects and so on
.


　　As an important microecological preparation, probiotics have been found in previous experiments that Lactobacillus rhamnosus can participate in the regulation of the immune system and exert probiotic effects.
Modulators of immune signaling pathways are involved in scientific research on tumor therapy
.

　　Mice aged 6-8 weeks were selected to participate in the study and divided into 4 groups (10 mice in each group), namely control group (normal saline + isotype antibody), Probio-M9 single treatment group (Probio-M9 + isotype antibody), PD- 1 Antibody monotherapy group (normal saline + PD-1 antibody) and combined treatment group (Probio-M9 + PD-1 antibody)
.
After the end of adaptive feeding, the mice were treated with antibiotics and inoculated with CT26 cells to simulate tumors.
The experiments were carried out for 24 days, and the tumor size was measured after the experiment
.

　　Probio-M9 and mixed probiotics containing Probio-M9 in PD-1 antibody therapy were compared and

　　compared Lactobacillus rhamnosus Probio-M9 single strain and Lactobacillus rhamnosus Probio-M9 complex strain on tumor treatment effect.
Among them, Lactobacillus casei Zhang was also added to the compound strain formula; the relative tumor proliferation rate, relative tumor inhibition rate and other indicators of mice were detected
.


　　The results showed that the combined application of Lactobacillus rhamnosus Probio-M9 and aPD-1 can enhance the effect of aPD-1 on tumor inhibition, and its relative tumor inhibition rate can reach up to 32%, while the tumor proliferation rate is only 68%; the therapeutic effect is excellent.
for the treatment of compound strains
.
This indicates that a sufficient amount of Lactobacillus rhamnosus Probio-M9 can promote the response of mice to PD-1 treatment, and the single strain can exert a corresponding probiotic effect compared with the composite strain
.


　　In conclusion, the combined treatment of Lactobacillus rhamnosus Probio-M9 and PD-1 antibody can significantly inhibit tumor growth, and the effect is better than that of PD-1 treatment alone; Probio-M9 can also stimulate the immune system and promote the enrichment of various immune cells.
To increase the response rate of PD-1, inhibit tumor growth, and improve survival rate to achieve prolonged survival
.
The experiment also found that a sufficient amount of Probio-M9 single-strain combination therapy can achieve a good probiotic effect, and its relative tumor inhibition rate is as high as 32%!

　　Ketuo Bio has always adhered to scientific research and continuous innovation, and cooperated with many domestic universities, research institutes and enterprises to isolate, identify and preserve 21,268 strains of lactic acid bacteria from naturally fermented foods, healthy people's intestines and breast milk from all over Asia, and built an Asian The largest resource bank of lactic acid bacteria strains
.
A total of 60 clinical trials have been carried out in cooperation with more than ten domestic top-three hospitals, and the effect is remarkable
.
In the future, Ketuo Bio will continue to innovate, continue to create "Chinese bacteria" and adhere to the industrial application of its own strains to help the healthy development of China's probiotics industry!

---

　　Immune checkpoint inhibitors represented by PD-1/PD-L1 inhibitors alone still have many problems in cancer treatment, the most important being the low response rate! Studies have shown that the response rate of cancer patients treated with drugs targeting PD-1/PD-L1 alone does not exceed 40%
.
In addition, there is a slow onset, the onset time is more than 12 weeks; the treatment effect is poor; it is easy to cause minor side effects and so on
.


　　As an important microecological preparation, probiotics have been found in previous experiments that Lactobacillus rhamnosus can participate in the regulation of the immune system and exert probiotic effects.
Modulators of immune signaling pathways are involved in scientific research on tumor therapy
.

　　Mice aged 6-8 weeks were selected to participate in the study and divided into 4 groups (10 mice in each group), namely control group (normal saline + isotype antibody), Probio-M9 single treatment group (Probio-M9 + isotype antibody), PD- 1 Antibody monotherapy group (normal saline + PD-1 antibody) and combined treatment group (Probio-M9 + PD-1 antibody)
.
After the end of adaptive feeding, the mice were treated with antibiotics and inoculated with CT26 cells to simulate tumors.
The experiments were carried out for 24 days, and the tumor size was measured after the experiment
.

　　Probio-M9 and mixed probiotics containing Probio-M9 in PD-1 antibody therapy were compared and

　　compared Lactobacillus rhamnosus Probio-M9 single strain and Lactobacillus rhamnosus Probio-M9 complex strain on tumor treatment effect.
Among them, Lactobacillus casei Zhang was also added to the compound strain formula; the relative tumor proliferation rate, relative tumor inhibition rate and other indicators of mice were detected
.


　　The results showed that the combined application of Lactobacillus rhamnosus Probio-M9 and aPD-1 can enhance the effect of aPD-1 on tumor inhibition, and its relative tumor inhibition rate can reach up to 32%, while the tumor proliferation rate is only 68%; the therapeutic effect is excellent.
for the treatment of compound strains
.
This indicates that a sufficient amount of Lactobacillus rhamnosus Probio-M9 can promote the response of mice to PD-1 treatment, and the single strain can exert a corresponding probiotic effect compared with the composite strain
.


　　In conclusion, the combined treatment of Lactobacillus rhamnosus Probio-M9 and PD-1 antibody can significantly inhibit tumor growth, and the effect is better than that of PD-1 treatment alone; Probio-M9 can also stimulate the immune system and promote the enrichment of various immune cells.
To increase the response rate of PD-1, inhibit tumor growth, and improve survival rate to achieve prolonged survival
.
The experiment also found that a sufficient amount of Probio-M9 single-strain combination therapy can achieve a good probiotic effect, and its relative tumor inhibition rate is as high as 32%!

　　Ketuo Bio has always adhered to scientific research and continuous innovation, and cooperated with many domestic universities, research institutes and enterprises to isolate, identify and preserve 21,268 strains of lactic acid bacteria from naturally fermented foods, healthy people's intestines and breast milk from all over Asia, and built an Asian The largest resource bank of lactic acid bacteria strains
.
A total of 60 clinical trials have been carried out in cooperation with more than ten domestic top-three hospitals, and the effect is remarkable
.
In the future, Ketuo Bio will continue to innovate, continue to create "Chinese bacteria" and adhere to the industrial application of its own strains to help the healthy development of China's probiotics industry!

---

---